A pilot study with flow mediated skin fluorescence: A novel device to assess microvascular endothelial function in coronary artery disease
Abstract
Background: Endothelial dysfunction is one of the earliest vascular manifestations in the pathogenesis of cardiovascular disease. Noninvasive, simple, and inexpensive methods of endothelial function assessment are therefore needed.
Methods: Microvascular endothelial function was assessed in coronary artery disease (CAD) patients by flow mediated skin fluorescence (FMSF), based on measurements of reduced form of nicotinamide adenine dinucleotide (NADH) fluorescence intensity during brachial artery occlusion (ischemic response [IRmax]) and immediately after occlusion (hyperemic response [HRmax]). Additionally, plasma levels of asymmetric dimethylarginine (ADMA) and endothelin-1 (ET-1) were measured to assess the association between biochemical markers and microvascular function evaluated in vivo by FMSF.
Results: A significant inverse correlation was found between ADMA levels and hyperemic response (r = –0.534, p = 0.003), while ET-1 levels were inversely related to the ischemic response (r= –0.575, p = 0.001). Both IR and HR were found lowest in patients with advanced CAD and diabetes. When the repeatability of the method was tested, the intraclass correlation coefficient for IRmax and HRmax were 0.985 (p < 0.001) and 0.914 (p < 0.001), respectively. Moreover, in Bland and Altman analysis, both variables IRmax and HRmax showed good agreement in repeated measurements.
Conclusions: In this pilot study, it was demonstrated that NADH fluorescence measured by FMSF device in CAD patients was associated with established plasma endothelial markers, and that both ischemic and hyperemic response were blunted in patients with advanced disease and diabetes. Furthermore, FMSF device showed excellent repeatability and good agreement for repeated measurements. However, further study is warranted to confirm these results in a larger patient cohort. (Cardiol J 2018; 25, 1: 120–127)
Keywords: endotheliumendothelial plasma markersmicrocirculationflow mediated skin fluorescenceNADH fluorescencebrachial artery occlusioncoronary artery disease
References
- Hellmann M, Roustit M, Cracowski JL. Skin microvascular endothelial function as a biomarker in cardiovascular diseases? Pharmacol Rep. 2015; 67(4): 803–810.
- Flammer AJ, Anderson T, Celermajer DS, et al. The assessment of endothelial function: from research into clinical practice. Circulation. 2012; 126(6): 753–767.
- Sibal L, Agarwal SC, Home PD, et al. The role of asymmetric dimethylarginine (ADMA) in endothelial dysfunction and cardiovascular disease. Curr Cardiol Rev. 2010; 6(2): 82–90.
- Gras E, Belaidi E, Briançon-Marjollet A, et al. Endothelin-1 mediates intermittent hypoxia-induced inflammatory vascular remodeling through HIF-1 activation. J Appl Physiol. 2016; 120(4): 437–443.
- Spieker LE, Lüscher TF, Noll G. ETA receptors mediate vasoconstriction of large conduit arteries during reduced flow in humans. J Cardiovasc Pharmacol. 2003; 42(3): 315–318.
- Roustit M, Cracowski JL. Assessment of endothelial and neurovascular function in human skin microcirculation. Trends Pharmacol Sci. 2013; 34(7): 373–384.
- Mayevsky A, Rogatsky GG. Mitochondrial function in vivo evaluated by NADH fluorescence: from animal models to human studies. Am J Physiol Cell Physiol. 2007; 292(2): C615–C640.
- Balu M, Mazhar A, Hayakawa CK, et al. In vivo multiphoton NADH fluorescence reveals depth-dependent keratinocyte metabolism in human skin. Biophys J. 2013; 104(1): 258–267.
- Piotrowski L, Urbaniak M, Jedrzejczak B, et al. Flow mediated skin fluorescence: A novel technique for evaluation of cutaneous microcirculation. Rev Sci Instrum. 2016; 87(3): 36111.
- Hellmann M, Tarnawska M, Dudziak M, et al. Reproducibility of flow mediated skin fluorescence to assess microvascular function. Microvasc Res. 2017; 113: 60–64.
- Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013; 34(38): 2949–3003.
- Perticone F, Sciacqua A, Maio R, et al. Asymmetric dimethylarginine, L-arginine, and endothelial dysfunction in essential hypertension. J Am Coll Cardiol. 2005; 46(3): 518–523.
- Böger RH, Bode-Böger SM, Szuba A, et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation. 1998; 98(18): 1842–1847.
- Hsu CP, Lin SJ, Chung MY, et al. Asymmetric dimethylarginine predicts clinical outcomes in ischemic chronic heart failure. Atherosclerosis. 2012; 225(2): 504–510.
- Yuki K, Miyauchi T, Kakinuma Y, et al. Mitochondrial dysfunction increases expression of endothelin-1 and induces apoptosis through caspase-3 activation in rat cardiomyocytes in vitro. J Cardiovasc Pharmacol. 2000; 36(5 Suppl 1): S205–S208.
- Ballinger SW. Mitochondrial dysfunction in cardiovascular disease. Free Radic Biol Med. 2005; 38(10): 1278–1295.
- Pouli D, Balu M, Alonzo CA, et al. Imaging mitochondrial dynamics in human skin reveals depth-dependent hypoxia and malignant potential for diagnosis. Sci Transl Med. 2016; 8(367): 367ra169.
